Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that cyproterone acetate with ethynyl estradiol improved acne and seborrhea within 3–6 months in women, but had less satisfactory results for alopecia and hirsutism.

This article reviews polycystic ovary syndrome in adolescents, highlighting its endocrine and metabolic features, and reports no new clinical findings; the etiology may involve early-life abnormalities in androgen production.

This review discusses severe insulin resistance syndromes, highlighting their diagnostic challenges, potential novel therapies like leptin replacement, and suggests metformin and lifestyle changes in its absence; no new clinical results are reported.

This review explores current and emerging treatments for polycystic ovary syndrome, focusing on managing hyperandrogenism and cardiometabolic risk, but reports no new clinical results.

This review examines the role of androgens in cutaneous disorders and the potential therapeutic effects of different oral contraceptives, noting variations in individual responses and the influence of genetic and local factors but reports no new clinical results.

This article discusses the diverse symptoms and treatment options for polycystic ovary syndrome, emphasizing diligent management of its metabolic component, but reports no new findings.

This review discusses the impact of testosterone therapy on postmenopausal women's sexual function and well-being but notes a lack of long-term safety studies and debates on defining androgen insufficiency.

This review discusses skin diseases related to contraceptive use, reporting potential issues with oral contraceptives and infrequent reactions to mechanical or barrier methods without new clinical findings.

This review discusses the role of hormonal influences and antiandrogenic treatments in managing hirsutism and other androgenic manifestations in women, highlighting cyproterone acetate as a beneficial option for cosmetically sensitive patients, and reports no new clinical results.

This article discusses the positive effects of estrogens and progestagens on various general diseases, but reports no new clinical results; the mechanisms and treatment approaches are presented.

This letter highlights that levonorgestrel intrauterine devices may lead to fewer systemic side effects, like acne, compared to its oral administration due to lower systemic levels of progestogens.

In this study, oral dienogest combined with ethinylestradiol provided effective contraception with a Pearl Index of approximately 0.2 and improved androgenic symptoms without significant metabolic effects.

This study concluded that combined hormonal contraceptives containing desogestrel, drospirenone, or cyproterone acetate were associated with a higher risk of venous thromboembolism compared to those containing levonorgestrel.

This review summarizes the use of chlormadinone acetate for hormone replacement therapy and contraception, highlighting its anti-androgenic effects, contraceptive efficacy, and clinical tolerability, without offering new clinical results.

This review discusses the 2011 publications on the side effects of sex hormones and related compounds, without reporting new clinical results.

This article reviews the contraceptive agent Depo-Provera, discussing its effectiveness, potential side effects, and safety concerns, but reports no new clinical results.

This study found that hair steroid profiling is a feasible, non-invasive alternative to serum analysis in adolescents, with androgen levels correlating more strongly with body size and composition in boys than girls.

This review evaluates therapies for hyperandrogenism, highlighting cyproterone acetate as the preferred treatment due to its potency and tolerability in managing symptoms in women.

This article discusses the complexities of androgen and antiandrogen therapies in women, detailing diagnostic measures, the effects on libido, and the potential benefits of new progestins with antiandrogenic properties, but presents no new empirical findings.

This review discusses the use of ethinylestradiol combined with antiandrogenic progestin for treating androgenisation symptoms and improving metabolic and menstrual health in women, but it does not provide new clinical data.

This study found that the progestins norgestimate and dienogest may help treat clinical hyperandrogeny in women by inhibiting skin 5 alpha-reductase activity with minimal androgenic potential.

This article discusses the androgenicity of progestins used in hormonal contraceptives and its potential impact on female pattern hair loss, but reports no new clinical findings.

This study found that two new progesterone derivatives showed higher antiandrogenic effects and 5α-reductase inhibition than finasteride in hamsters, particularly reducing seminal vesicle weight and flank organ size.

This study found that A-ring reduced derivatives of norethisterone and levonorgestrel exhibit estrogen-like potency in rat osteoblasts, suggesting a mechanism for 19-norprogestins' bone restoration effects in postmenopausal women.

Hormonal contraceptives and therapies regulate organ functions and treat various conditions.

This article reviews non-biodegradable progestational subdermal implants as long-acting contraceptives for women, discussing their effectiveness, associated side effects, and implementation challenges without reporting new clinical results.

This study found that four new progesterone derivatives reduced prostate weight in gonadectomized hamsters, suggesting potent in vivo antiandrogenic effects similar to finasteride.

This article suggests using oral contraceptives with antiandrogenic properties for women with virilization symptoms like acne and advises higher doses of antiandrogens for severe acne, androgenic alopecia, or idiopathic hirsutism.

This study reports that five new progesterone derivatives demonstrated inhibitory activity against the 5α-reductase enzyme and binding affinity for the androgen receptor in an in vitro hamster model.

This study found that pregnane derivatives with higher lipophilicity, like compound 9d, had stronger androgen receptor binding and greater antiandrogenic effects in rats, correlating relative binding affinity with log P values.